Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | MYC | P01106 | 2/20 | 0.64 |
| ▸ | MAX | P61244 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | CTSV | O60911 | 1/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CDC25B | P30305 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22720195 | 0.90 | CTSV (0.78) | AKR1C3AKR1C2MEN1KMT2AMYC | |
| SCHEMBL6141339 | 0.89 | CTSV (0.76) | AKR1C3AKR1C2MEN1KMT2AMYC | |
| SCHEMBL10956197 | 0.88 | MAPT (0.64) | AKR1C3AKR1C2MEN1KMT2AGFER | |
| SCHEMBL22720115 | 0.87 | MYC (0.65) | AKR1C3AKR1C2MEN1KMT2AMYC | |
| SCHEMBL18667006 | 0.86 | HCAR3 (0.72) | AKR1C3AKR1C2MEN1KMT2AMYC | |
| SCHEMBL453183 | 0.85 | AKR1C3 (0.68) | AKR1C3AKR1C2MEN1KMT2AMYC | |
| SCHEMBL21248526 | 0.85 | AKR1C3 (0.67) | AKR1C3AKR1C2MEN1KMT2AGFER | |
| SCHEMBL23567 | 0.85 | AKR1C3 (0.67) | AKR1C3AKR1C2MEN1KMT2AGFER | |
| SCHEMBL2646698 | 0.85 | AKR1C3 (0.71) | AKR1C3AKR1C2MEN1KMT2AMYC | |
| SCHEMBL2112961 | 0.85 | AKR1C3 (0.67) | AKR1C3AKR1C2MEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183000-B1 | 2, 4-dinitroanilino-benzoic acid: novel insulinotropic agent for the treatment of diabetes | JAHAN HUMERA (PK) | 2019-01-22 | — | — | US | claimed |
| US-9381182-B2 | Anthranilic acid derivatives: novel inhibitors of advanced glycation end-products (AGEs) formation | CHOUDHARY MUHAMMAD IQBAL (PK) | 2016-07-05 | — | — | US | claimed |
| US-10183000-B1 | 2, 4-dinitroanilino-benzoic acid: novel insulinotropic agent for the treatment of diabetes | JAHAN HUMERA (PK) | 2019-01-22 | — | — | US | disclosed |
| US-10183000-B1 | 2, 4-dinitroanilino-benzoic acid: novel insulinotropic agent for the treatment of diabetes | JAHAN HUMERA (PK) | 2019-01-22 | — | — | US | disclosed |
| US-9312497-B2 | Heterocyclic compound, organic light-emitting diode including the heterocyclic compound, and flat display device including the organic light-emitting diode | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-04-12 | — | — | US | disclosed |
| US-20150051286-A1 | ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION | CHOUDHARY MUHAMMAD IQBAL (PK) | 2015-02-19 | — | — | US | disclosed |
| US-20150051286-A1 | ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION | CHOUDHARY MUHAMMAD IQBAL (PK) | 2015-02-19 | — | — | US | disclosed |
| US-20120135864-A1 | POLLINATION IMPROVER | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2012-05-31 | — | — | US | disclosed |
| US-20120108431-A1 | PLANT GROWTH REGULATOR ADDITIVE | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2012-05-03 | — | — | US | disclosed |
| US-20120088667-A1 | SAFENING AGENT | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2012-04-12 | — | — | US | disclosed |
| US-6288065-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON*S AND ALZHEIMER*S DISEASE | SCHERING AKTIENGESEELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| US-6057304-A | Quinoxaline-phosphonic acid derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
| CN-1038840-C | para-dinitrogen naphthalene derivative, its preparation method and its medical use | SCHERING AG (DE) | 1998-06-24 | — | — | CN | disclosed |
| EP-0565683-A1 | QUINOXALINE DERIVATES WITH AFFINITY FOR QUISQUALATE-RECEPTORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-10-20 | — | — | EP | disclosed |
| CN-1072929-A | Para-dinitronaphthalene derivative, preparation method and medical application thereof | SCHERING AG (DE) | 1993-06-09 | — | — | CN | disclosed |
| WO-1993008173-A1 | QUINOXALINE DERIVATES WITH AFFINITY FOR QUISQUALATE-RECEPTORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051286-A1 | ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION | AGER, NFKBIA, DNPEP | AKR1C3 978/4885AKR1C2 734/4885MEN1 3683/4885 |
| US-20120088667-A1 | SAFENING AGENT | PIN1, IPO11, XPO1 | AKR1C3 783/4885AKR1C2 1055/4885MEN1 1807/4885 |
| US-20120135864-A1 | POLLINATION IMPROVER | AADAT, TIPARP, GSR | AKR1C3 62/4885AKR1C2 159/4885MEN1 3460/4885 |
| US-20120108431-A1 | PLANT GROWTH REGULATOR ADDITIVE | MYB, ING2, AGXT | AKR1C3 1005/4885AKR1C2 537/4885MEN1 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.